Biotechnology Value Fund, L.P. and affiliated reporting persons amended their Schedule 13G/A to disclose shared beneficial ownership and exercisable pre-funded warrants in TScan Therapeutics. As of March 31, 2026, the Reporting Persons held Pre-Funded Warrants exercisable for an aggregate of 8,784,348 shares, with exercise limited by a 9.99% blocker.
The filing states BVF beneficially owned 3,014,267 shares (5.4%), BVF2 beneficially owned 1,868,548 shares (3.3%), and Trading Fund OS beneficially owned 560,400 shares (1.0%). Aggregated positions are reported as 5,578,288 shares (9.99%) for Partners, BVF Inc., and Mr. Lampert; BVF GPH may be deemed to own 4,882,815 shares (8.7%). The filing cites 52,625,035 shares outstanding as of February 27, 2026 and notes 3,199,687 shares issued on March 27, 2026 upon prior exercises; 13,998 shares remain issuable under the Pre-Funded Warrants within the blocker limit.
Positive
None.
Negative
None.
Insights
Schedule 13G/A reports aggregated beneficial ownership and exercise limits tied to non‑expiring pre‑funded warrants.
The filing discloses 8,784,348 shares underlying Pre‑Funded Warrants exercisable at <$0.0001> and subject to a 9.99% exercise blocker. It details which entities may be deemed beneficial owners through GP and manager relationships and includes multiple formal disclaimers of beneficial ownership.
Key dependencies include the issuer's outstanding share count (52,625,035 as of February 27, 2026) and prior exercises on March 27, 2026. Cash‑flow treatment is not addressed in the excerpt; future filings would reflect further exercises or ownership changes.
The group reports near‑10% aggregated economic exposure through shares and exercisable warrants, constrained by a 9.99% blocker.
The filing lists aggregate beneficial holdings of 5,578,288 shares for Partners/BVF Inc./Mr. Lampert and notes sizeable additional warrant capacity (8,784,348 underlying shares), although the blocker restricts immediate conversion to a small number (13,998 currently exercisable without breaching 9.99%).
Reporting persons are organized through GP and management entities; voting/dispositive powers are shared as shown. The actual potential dilution depends on future exercises and adherence to the blocker; cash‑flow treatment is not specified in the excerpt.
Shares underlying Pre‑Funded Warrants8,784,348 sharesaggregate exercisable underlying warrants, as of March 31, 2026
BVF beneficially owned3,014,267 sharesBVF position, 5.4% of class as of March 31, 2026
BVF2 beneficially owned1,868,548 sharesBVF2 position, 3.3% of class as of March 31, 2026
Trading Fund OS beneficially owned560,400 sharesTrading Fund OS position, 1.0% of class as of March 31, 2026
Shares outstanding used52,625,035 sharesShares outstanding as of February 27, 2026 used for percentage calculations
Shares issued on March 27, 20263,199,687 sharesShares issued upon exercise of certain Pre‑Funded Warrants on March 27, 2026
Aggregated reported ownership5,578,288 sharesAggregate beneficial holdings attributed to Partners/BVF Inc./Mr. Lampert, ~9.99% of class
Blocker limit exercisable13,998 sharesNumber of shares currently exercisable under the Pre‑Funded Warrants without exceeding 9.99% blocker
Key Terms
Pre‑Funded Warrant, Pre‑Funded Warrants Blocker, Beneficially owned, Shared dispositive power
4 terms
Pre‑Funded Warrantfinancial
"held Pre‑Funded Warrants exercisable for an aggregate of 8,784,348 Shares"
Pre‑Funded Warrants Blockerregulatory
"the "Pre‑Funded Warrants Blocker" limits the exercise of the Pre‑Funded Warrants"
Beneficially ownedregulatory
"BVF beneficially owned 3,014,267 Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
BVF reports beneficial ownership of 3,014,267 shares (5.4%) as of March 31, 2026. The filing states this total includes 13,998 shares issuable under Pre‑Funded Warrants subject to a 9.99% blocker and excludes other warrant‑underlying shares.
How many shares do the Reporting Persons hold via pre‑funded warrants?
The Reporting Persons and a Partners managed account held Pre‑Funded Warrants exercisable for an aggregate of 8,784,348 shares. The warrants are exercisable at $0.0001 per share and subject to the filing’s stated 9.99% blocker on exercises.
What is the company share count used to calculate percentages?
Percentages are based on a denominator of 52,625,035 shares outstanding as of February 27, 2026, plus 3,199,687 shares issued on March 27, 2026 from prior warrant exercises and 13,998 shares issuable under certain Pre‑Funded Warrants referenced in the filing.
Does the filing show who controls voting or disposition rights?
Yes. The filing indicates shared voting and dispositive power among related entities (GPs, Partners, BVF GPH) over the reported shares. Specific sole versus shared powers are listed on the cover page items referenced in the statement.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
TScan Therapeutics, Inc.
(Name of Issuer)
Voting Common Stock, $0.0001 par value per share
(Title of Class of Securities)
89854M101
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND L P
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,014,267.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,014,267.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,014,267.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
BVF I GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,014,267.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,014,267.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,014,267.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND II LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,868,548.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,868,548.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,868,548.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
BVF II GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,868,548.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,868,548.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,868,548.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
Biotechnology Value Trading Fund OS LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
560,400.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
560,400.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
560,400.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
BVF Partners OS Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
560,400.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
560,400.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
560,400.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.0 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
BVF GP HOLDINGS LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,882,815.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,882,815.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,882,815.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.7 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
BVF PARTNERS L P/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,578,288.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,578,288.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,578,288.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
BVF INC/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,578,288.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,578,288.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,578,288.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
89854M101
1
Names of Reporting Persons
LAMPERT MARK N
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,578,288.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,578,288.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,578,288.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
TScan Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
Item 2.
(a)
Name of person filing:
Biotechnology Value Fund, L.P. ("BVF")
BVF I GP LLC ("BVF GP")
Biotechnology Value Fund II, L.P. ("BVF2")
BVF II GP LLC ("BVF2 GP")
Biotechnology Value Trading Fund OS LP ("Trading Fund OS")
BVF Partners OS Ltd. ("Partners OS")
BVF GP Holdings LLC ("BVF GPH")
BVF Partners L.P. ("Partners")
BVF Inc.
Mark N. Lampert ("Mr. Lampert")
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)
Address or principal business office or, if none, residence:
Biotechnology Value Fund, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF I GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Fund II, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF II GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Trading Fund OS LP
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF Partners OS Ltd.
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF GP Holdings LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Partners L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Inc.
44 Montgomery St., 40th Floor
San Francisco, California 94104
Mark N. Lampert
44 Montgomery St., 40th Floor
San Francisco, California 94104
(c)
Citizenship:
Biotechnology Value Fund, L.P.
Delaware
BVF I GP LLC
Delaware
Biotechnology Value Fund II, L.P.
Delaware
BVF II GP LLC
Delaware
Biotechnology Value Trading Fund OS LP
Cayman Islands
BVF Partners OS Ltd.
Cayman Islands
BVF GP Holdings LLC
Delaware
BVF Partners L.P.
Delaware
BVF Inc.
Delaware
Mark N. Lampert
United States
(d)
Title of class of securities:
Voting Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
89854M101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on March 31, 2026, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held Pre-Funded Warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 8,784,348 Shares. The Pre-Funded Warrants are exercisable at any time at an exercise price of $0.0001 per Share and do not expire. A holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants which, upon giving effect to such exercise, would cause the aggregate number of Shares beneficially owned by the holder (together with its affiliates and other attribution parties (as defined in the Pre-Funded Warrant)) to exceed 9.99% of the Shares outstanding immediately after such exercise (the "Pre-Funded Warrants Blocker"). As of the close of business on March 31, 2026, the Pre-Funded Warrants Blocker limits the exercise of the Pre-Funded Warrants held by the Reporting Persons and the Partners Managed Account to 13,998 out of the 8,784,348 Shares underlying the Pre-Funded Warrants held by them.
As of the close of business on March 31, 2026, (i) BVF beneficially owned 3,014,267 Shares, including 13,998 Shares underlying certain Pre-Funded Warrants held by it and excluding 4,658,896 Shares underlying certain Pre-Funded Warrants held by it, (ii) BVF2 beneficially owned 1,868,548 Shares, excluding 3,733,846 Shares underlying the Pre-Funded Warrants held by it, and (iii) Trading Fund OS beneficially owned 560,400 Shares, excluding 303,238 Shares underlying the Pre-Funded Warrants held by it.
BVF GP, as the general partner of BVF, may be deemed to beneficially own the 3,014,267 Shares beneficially owned by BVF.
BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,868,548 Shares beneficially owned by BVF2.
Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 560,400 Shares beneficially owned by Trading Fund OS.
BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 4,882,815 Shares beneficially owned in the aggregate by BVF and BVF2.
Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 5,578,288 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 135,073 Shares held in the Partners Managed Account, which excludes 74,370 Shares underlying the Pre-Funded Warrants held in the Partners Managed Account.
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 5,578,288 Shares beneficially owned by Partners.
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 5,578,288 Shares beneficially owned by BVF Inc.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
(b)
Percent of class:
The following percentages are based upon a denominator that is the sum of: (i) 52,625,035 Shares outstanding as of February 27, 2026, which is the total number of Shares outstanding as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2026, (ii) 3,199,687 Shares issued to the Reporting Persons and Partners Managed Account on March 27, 2026 upon the exercise of certain Pre-Funded Warrants previously held by the Reporting Persons and Partners Managed Account, as applicable, and (iii) 13,998 Shares issuable upon the exercise of certain Pre-Funded Warrants held by the Reporting Persons, as applicable.
As of the close of business on March 31, 2026, (i) BVF beneficially owned approximately 5.4% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.3% of the outstanding Shares, (iii) Trading Fund OS beneficially owned approximately 1.0% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.4% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.3% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own approximately 1.0% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 8.7% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Cover Pages Items 5-9.
(ii) Shared power to vote or to direct the vote:
See Cover Pages Items 5-9.
(iii) Sole power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
(iv) Shared power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on June 5, 2023.
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
